type of intervention; statistical methods, and results. Whenever possible absolute changes were presented to reflect differences between two groups (biological agent opposed to control) or two time points (before and after). The data extraction was checked by a second author (AG).
Statistical analysis
A meta-analysis to assess the overall effect of biological agents on work participation in RA could not be performed due to extended heterogeneity with respect to study populations, outcome measures and statistical analysis. Therefore, narrative summaries are provided.
RESULTS

Study selection and inclusion
A total of 774 titles was identified after the electronic search. Sixty-two articles were selected for full text review as shown in the flowchart in figure 2. Eventually, 25 full text articles were selected for quality assessment. Six additional articles were excluded as they did not report the direct effect of biological agents on work productivity, but the relation between treatment response and work outcome, independent of treatment assignment. [2, [18] [19] [20] [21] [22] Finally, 19 articles were included: six uncontrolled cohorts, [23] [24] [25] [26] [27] [28] seven controlled cohorts, [4, [29] [30] [31] [32] [33] [34] and six RCTs. [10, [35] [36] [37] [38] [39] Quality assessment cohort studies
Study results
In total 11 259 patients were treated with biological agents: 8015 in cohorts and 3244 patients in RCTs. Ten studies (all controlled or uncontrolled cohorts) were single country studies with six performed in Europe and four in USA/Canada. Nine studies were multinational (three cohorts and six RCTs) with countries from Europe, USA, Canada and Australia. Almost all studies used self-reported outcome measures except for two controlled cohorts. In uncontrolled cohorts, patients had an average age of 51.6 years and average disease duration of 10.9 years. For the controlled cohorts this was 51.1 and 11.8 years, respectively, and for RCTs 50.5 and 4.5 years, respectively. The biological agents considered were TNFα inhibitors in 18 articles; etanercept in three, adalimumab in seven, infliximab in one, certolizumab pegol in one or different biological agents seen as a group in six articles. One study reported effects of abatacept on work. Tables 1 -3 show the results of uncontrolled cohorts, controlled cohorts and RCTs, respectively. Controlled cohorts are ordered by comparator: general population (n=1), or continuation of usual care with disease modifying antirheumatic drugs (DMARD). RCTs are ordered by comparator methotrexate in methotrexate-naive patients or methotrexate/DMARD continuation in methotrexate/DMARD or anti-TNF failures. Within each design, studies are ranked according to the date of publication. In the last column of this tables, the letters correspond to the criteria (figure 1) with a negative/inadequate quality score or with insufficient information (in brackets).
Employment status
Employment status was the most frequently explored work outcome: nine out of 13 cohorts, [4, 23, 26, 28, 29, [31] [32] [33] [34] and five of 6 RCTs. [35-37, 39, 40] . Follow-up varied from 12 to 104 weeks.
One uncontrolled cohort study showed a temporary positive effect after 1 year treatment (mean +4.1 h/week), but this effect was lost after 5 years. [23] The remaining two uncontrolled studies showed no effect. [26, 28] Two controlled cohorts showed that employed anti-TNF-treated patients worked an additional 0.61 years or that 20% more patients remained employed compared with the control group that started methotrexate/leflunomide or continued usual care, respectively. [31, 34] Another controlled cohort study showed no effect of biological agents versus matched controls receiving usual care (DMARD), but a positive effect on employment status in patients with short disease duration (<11 years) was seen. [29] The three remaining controlled cohorts, one of which used the general population as control, showed no effect. [4, 32, 33] Two out of 5 RCTs showed a positive effect on employment status after 52 and 104 weeks of treatment with a biological agent, both in methotrexate-naive patients starting methotrexate monotherapy as the active comparator. [35, 39] 20 articles were reviews or overviews 13 articles were Cost-Effectiveness Analysis 3 articles did not specify anti-TNF treatment on work/productivity 25 studies followed critical appraisal 6 studies did not measure work outcome directly 19 studies were included in this review:
-13 cohort studies -6 RCT studies
Figure 2
Flowchart of study selection and inclusion adalimumab monotherapy (OR 1.285; 95%CI 0.837 to 1.972). [39] It is of note that in that study not only regaining employment, but also remaining at work was contained in the definition of treatment success. A conflicting result on job loss was reported for abatacept in methotrexate or anti-TNF failures, when the response of the physical component of the short form 36 (SF-36) was mapped on job loss as seen in a historic population study. [37] The two remaining RCTs (follow-up between 54 and 56 weeks) showed no effect of adalimumab or infliximab when comparing to biological agents to methotrexate in methotrexate failures. [36, 40] Absence from paid work Absence from work was the outcome that most frequently showed a favourable effect of biological agents. Six out of 13 cohort studies [25-28, 30, 32] and four of six RCTs [35, [38] [39] [40] quantified the effect of biological agents on absenteeism. Follow-up varied from 12 to 104 weeks. All cohort studies reported a reduction in absence from work. Four studies were uncontrolled [25] [26] [27] [28] and two controlled; one of which used a general population as comparator [32] and one compared anti-TNF with usual care with DMARDs. [30] In the uncontrolled studies improvements ranged from 0.5 days in 1 year in the total group (workers and non-workers), [26] to 0.5 days in the last 2 weeks after 12 weeks in those with paid work. [28] The general population controlled study reported a decrease of the RR (decreased from 6.6 to 5.1) for being on sick leave during the first year after initiation of biological agents when compared with general population data, but compared with one year before treatment no difference was noticed. [32] This suggests patients returned to the sick leave rate before the increase of sick leave surrounding the initiation of biological agents. Moreover, only completers were included in this analysis.
All four RCTs assessing absenteeism showed a reduction by biological agents in absence from paid work compared with methotrexate monotherapy in methotrexate-naive patients [35, 39, 40] or continuation of methotrexate in methotrexate failures. [38] Reduction by biological agents in days of sick leave ranged from 2.1 days in the past 4 weeks [38] to 18.7 days in 2 years, [39] and more patients treated with infliximab had no days absent compared with the control group (78.9% versus 66.6%, respectively, p<0.01). [40] . In a trial in methotrexate failures, certolizumab pegol was not able to reduce absenteeism It showed that beneficial effects after 6 months of treatment with etanercept were not maintained after one year. [30] Three RCTs reported a significant (small) improvement in presenteeism, two when comparing either etanercept or adalimumab with methotrexate monotherapy in methotrexate-naive patients [35, 36] or certolizumab pegol with continuing methotrexate in methotrexate failures. [38] Improvements compared with methotrexate ranged from 1.4% using the work limitations questionnaire to three points on a VAS (0-10). A conflicting result was seen with adalimumab as the combination of adalimumab and methotrexate in early, methotrexate-naïve patients reduced presenteeism significantly compared with methotrexate monotherapy (p<0.05), while adalimumab monotherapy was not able to improve presenteeism significantly. [39] One of these studies estimated presenteeism indirectly by mapping health assessment questionnaire (HAQ) changes on presenteeism as measured in another trial. [6, 35] 
DISCUSSION
This study reviewed all published articles that quantified the direct effect of biological agents on employment status, sick leave or presenteeism in patients with RA. As shown in table 4, biological agents have overall a positive effect on absence from paid work and presenteeism compared with the situation before start (n=7), the general population (n=1), or similar groups starting or continuing usual care with DMARD (n=9), while the effect on employment status remains undecided.
The main challenge of this review was the heterogeneity in study design, work related outcomes and patients included, hampering comparability. While we specifically aimed to include studies from all designs, each has advantages and limitations. RCTs typically have low external validity and follow-up is often too short to be relevant with regard to work outcome. Moreover, several RCTs with biological agents were performed in DMARD failing patients using a control group without active treatment. Of specific concern for RCTs was also that work participation was a secondary outcome in all but two studies. [35, 36] As a consequence, sample sizes could have been too small to show effects on employment status. 
N=3
1 study [23] 2 studies [26, 28] N=4 4 studies [25] [26] [27] [28] 
N=4
3 studies [24, 25, 27] 1 study [28] 
Controlled cohorts Positive results
Conflicting results Negative results
N=6
2 studies [31, 34] 1 study [29] 3 studies [4, 32, 33] N=2 2 studies [30, 32] 
N=1
1 study [30] RCT studies Positive results
Conflicting results Negative results
N=5
2 studies [35, 39] 1 study [37] 2 studies [36, 40] N=4 4 studies [35, [38] [39] [40] N=4 3 studies [35, 36, 38] 1 study [39] Finally, in the analyses often the between-group differences were not tested or presented. Although uncontrolled cohorts may be more generalizable and more informative with respect to the duration of the effect on work outcome, the absence of a control group cannot exclude regression to the mean as a cause of improvement, because patients are likely to start with biological agents when the disease flares. Also, results of uncontrolled cohorts might not be different from the expected course of intensive DMARD treatment. While the inclusion of an RA control group could adjust for the effect of non-biological treatments (e.g., non-biological DMARD), such studies cannot adjust for societal effects on the occurrence of sick leave and employment perspectives. This was shown in the study by Olofssen et al [32] who demonstrated that the risk of sick leave in patients, compared with the general population, decreased after the start of biological agents, but stabilised after 1 year on a level that was even higher than 1 year before the start of biological agents. Work outcomes can also be influenced by differences per country in legislation and changes in these legislations. Only this population study could take this into account. [32] Almost all studies used different approaches to assess work outcome comprising self-composed questionnaires, validated instruments or existing databases reporting on work outcomes. Although 24 instruments are available to assess absence from work and/or presenteeism, only a few studies used one of these instruments (work productivity and activity impairment questionnaire, RA-work impairment scale, work productivity survey-RA, work limitations questionnaire, workability index and health and labour questionnaire). [24, 25, 28, 35, 36, 38] Even than, comparability remains limited as these instruments also differ in recall, concepts for absenteeism and presenteeism and whether or not impact on work should be attributed to RA or overall health. Moreover, some studies presented results on a group level (means/median) while others on the individual patient level (proportion of patients with sick leave or presenteeism). Also, most studies used different definitions to describe employment status such as: being employed, additional years worked, work disability rate (official or self-perceived) and job loss. For example, one study defined employment status as differences between groups in gaining or remaining employed. [39] Another study reported on hours working per week, which made it unclear whether this referred to employment status (contract hours) or also included productivity loss due to sick leave. [23, 34] . Of interest were two studies that had not included a work outcome measure, but mapped health effects of SF-36/HAQ on those of another study which included a work outcome measure as well as SF-36/HAQ. As such, they could indirectly compare the effect of biological agents on work. [35, 39] Last but not least, the clinical relevance of effects is difficult to interpret because no efforts have been made to define minimal relevant differences for work outcomes.
Six articles were excluded from this review since they quantified the relation between response measures (e.g., disease activity score in 28 joints, HAQ, American college of rheumatology (ACR)/European league against rheumatism (EULAR) response) and work outcome as an indirect consequence of treatment with biological agents, independent of treatment allocation. [2, [18] [19] [20] [21] [22] These studies suggest that a main effect of biological agents on work participation is mediated by an improvement in disease. Whether biological agents have an additional effect compared with non-biological DMARDs, independent of the effect on improvement of disease activity and physical function, remains incompletely resolved because only a few of the studies in this review compared TNFα with intensive DMARD treatment. [41] A last issue limiting comparability concerned the study populations. For example, inclusion was sometimes limited to those of working age (18-64 years) or to those being employed. Within studies, subgroups were often selected to report different outcomes. While results on sick leave and presenteeism were usually reported for those employed, measures on employment status were often reported for the total group. Also, populations differed in risk of change in work participation and therefore reversibility of restrictions in work participation. In longstanding DMARD-resistant RA, it is likely that a large proportion of patients already withdrew from work. This reduces the chance biological agents further decreasing withdrawal rates. Moreover, return to work for persons with longstanding work disability is unlikely. In contrast, for patients with early active RA there might be 'a window of opportunity' for biological agents to reduce adverse work outcomes. [37] This seems likely in this review in which two of the four studies in early methotrexate-naive patients, [35, 39] and a subgroup analyses of patients with shorter disease duration in a cohort study, [29] showed positive effects on employment status.
Four studies (two uncontrolled studies [27, 28] and two RCTs [38, 39] assessed the effect of biological agents on unpaid work. All four studies showed improvement in unpaid work, but the change over time of differences between groups was only significant in three studies [28, 38, 39] (see supplementary appendix 2, available online only).
The checklists of the Dutch Cochrane Collaboration had some limitations, specifically when trying to decide on the relative importance of the different criteria.
[16] First, and as discussed above, it is difficult to judge whether evidence from RCTs weighs more or less than evidence from controlled cohorts. Also within one type of design, the relevance of the individual criteria are not difficult to weigh out against each other. For example the study of Zhang et al [28] could be considered a good quality cohort study (almost no questions with no or less information), but the follow-up period of this article is only 12 weeks, making it economically less relevant. Finally, some attributes of the outcomes could not be appraised for quality. As the recall period and the disease attribution (overall health or RA specific) were considered important to interpret the results, these criteria were added. As expected, these criteria often received a negative score. It is difficult, however, to hypothesise how this would influence the results. Criteria that most often scored negatively were the assessment of appropriate confounders and incomplete follow up of cohort studies (letters H and G). It was also striking that important determinants or confounders for work related outcomes such as educational level and job-related characteristics were never reported as baseline characteristics nor added as explanatory factors in further analyses. On line with this, it is noteworthy to mention that the impact of treatment on mortality in employed patients should also be considered when trying to understand the incremental lifetime (economic) impact of biological agents on work outcome.
In conclusion, although no pooled effect size could be calculated due to heterogeneity of all data, almost all studies showed positive results of biological agents on absenteeism and presenteeism compared with start/continue usual care with DMARD, the general population or the situation before starting biological agents. The effect on employment status was more conflicting, with only a fifth of the cohort studies reporting a positive result, opposed to 40% of the RCTs. It seems of interest that 50% of studies that assessed early methotrexate -naive patients showed a positive result on employment status. To enhance comparability of studies, consensus on preferred outcome instruments and recommendations on the conduct and reporting of studies on work participation is recommended.
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